Optical Sensor Bioavailability Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the bioavailability of therapeutic biologics in patients are costly, time-consuming, and ineffective, particularly due to immune responses and clearance mechanisms that reduce the efficacy of treatments for autoimmune disorders like rheumatoid arthritis.
Innovation Solution
A method using an optical sensor with capture probes to detect the presence or absence of biologics by measuring changes in resonance wavelengths, allowing for rapid assessment of bioavailability and potential immune responses, employing a system with a ring resonator and capture probes that selectively bind to therapeutic biologics and antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional assays are used to determine the presence of autoantibodies against therapeutic biologics, then measurement precision can be achieved, but the process becomes costly and time-consuming
Solution Approach 1:
The patent replaces traditional mechanical/chemical assay systems with an optical sensing system that uses light resonance to detect biologic-antibody complexes. The optical sensor measures resonance wavelength shifts when capture probes bind to biologics in the sample, providing rapid detection without the time-consuming steps of traditional assays while maintaining measurement precision through optical detection sensitivity.
2Measurement precision
If traditional assays are used to determine bioavailability, then measurement precision can be achieved, but the process becomes costly
Solution Approach 1:
The patent employs disposable optical sensor chips with immobilized capture probes that can be used once and then discarded. This eliminates the need for expensive, complex assay reagents and equipment maintenance associated with traditional methods. The low cost of individual sensor chips makes frequent monitoring affordable while maintaining detection accuracy through the specialized optical detection design.
3Productivity
If rapid detection methods are implemented, then productivity is improved, but measurement precision may deteriorate
Solution Approach 1:
The patent pre-immobilizes capture probes (such as TNFα or other target antigens) on the optical sensor surface before sample introduction. This preliminary preparation ensures that when the patient sample is introduced, the specific biologic-antibody binding occurs immediately and specifically on the sensor surface. The pre-positioned probes eliminate the need for complex incubation and washing steps required in traditional assays, enabling rapid detection while maintaining precision through specific binding.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid and reliable determination of biologic bioavailability, aiding in identifying non-responders and optimizing therapy by providing actionable results at the time of testing, thus improving treatment decisions.
Implementation Method 1
measuring a change, no substantial change, or no change in one or more resonance wavelengths at the optical sensor
Data Source
AI summary
Embodiments provided herein relate to methods, compositions and systems for rapid determination of the bioavailability of a therapeutic biologic in a sample from a subject. In some such embodiments, the presence or absence of a therapeutic biologic in a sample can be determined using an optical sensor